EQ vs. VIGL, PROC, CLYM, ENTA, SKYE, ATOS, XBIT, ALGS, EDIT, and ZURA
Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Vigil Neuroscience (VIGL), Procaps Group (PROC), Climb Bio (CLYM), Enanta Pharmaceuticals (ENTA), Skye Bioscience (SKYE), Atossa Therapeutics (ATOS), XBiotech (XBIT), Aligos Therapeutics (ALGS), Editas Medicine (EDIT), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry.
Equillium vs.
Vigil Neuroscience (NASDAQ:VIGL) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
Vigil Neuroscience presently has a consensus target price of $19.75, indicating a potential upside of 551.82%. Equillium has a consensus target price of $5.00, indicating a potential upside of 468.18%. Given Vigil Neuroscience's higher probable upside, equities analysts clearly believe Vigil Neuroscience is more favorable than Equillium.
Vigil Neuroscience has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.
In the previous week, Vigil Neuroscience had 1 more articles in the media than Equillium. MarketBeat recorded 1 mentions for Vigil Neuroscience and 0 mentions for Equillium. Equillium's average media sentiment score of 1.00 beat Vigil Neuroscience's score of 0.00 indicating that Equillium is being referred to more favorably in the news media.
Equillium has higher revenue and earnings than Vigil Neuroscience. Equillium is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 33.0% of Vigil Neuroscience shares are owned by company insiders. Comparatively, 30.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Vigil Neuroscience has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Vigil Neuroscience's return on equity.
Equillium received 5 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 83.78% of users gave Vigil Neuroscience an outperform vote while only 83.72% of users gave Equillium an outperform vote.
Summary
Vigil Neuroscience beats Equillium on 9 of the 16 factors compared between the two stocks.
Get Equillium News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Equillium Competitors List
Related Companies and Tools
This page (NASDAQ:EQ) was last updated on 2/22/2025 by MarketBeat.com Staff
